Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for the Prevention of Preeclampsia in Nulliparous Women After ART
NCT05625724Phase 3Recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Aug 2023
- Primary completion
- Aug 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aspirin in preeclampsia (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Incidence of preterm preeclampsia (<37 weeks of gestation) at 9 months. Started Aug 2023; status: recruiting.
02
Drugs
aspirin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT05625724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625724.